Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Fuzuloparib was approved in China in 2020 for treating ovarian and other solid cancers in patients with germline BRCA (breast cancer gene) receiving second-line or above chemotherapy. It is a Poly Adenosine diphosphate-Ribose Polymerase (PARP) inhibitor developed by Jiangsu Hengrui Medicine Co., Ltd. PARP inhibits DNA repair in cancer cells, induce... Read More»
Jingxi Li, Keheng Wu, Xue Li, Sihui Long, Zhou Zhou, Youni Zhao, Ranran Jia, Pingping Song, Jack Liu and Bo Liu
: J Clin Exp Pathol
10.4172/2161-0681-22.12.415Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article
Treatment of an Acute Respiratory Failure Child Caused by Special Airway Foreign Body
Da-bo Liu, Shu-yao Qiu, Zhen-yun Huang and Jian-wen Zhong
Research Article: Otolaryngology 2013, 3: 141
DOI:
A New Technique of Coblation used in 42 Infants with Epiglottic Cyst
Shu-yao Qiu, Da-bo Liu, Zhen-yun Huang and Jian-wen Zhong
Case Report: Otolaryngology 2013, 3: 135
DOI:
Make the best use of Scientific Research and information from our 700 + peer reviewed, 黑料网 Journals